Oxygen is vital to sustain life. However, breathing oxygen at higher than normal partial pressure leads to hyperoxia and can cause oxygen toxicity or oxygen poisoning . The clinical settings in which oxygen toxicity occurs is predominantly divided into two groups; one in which the patient is exposed to very high concentrations of oxygen for a short duration, and the second where the patient is exposed to lower concentrations of oxygen but for a longer duration. These two cases can result in acute and chronic oxygen toxicity, respectively. The acute toxicity manifests generally with central nervous system (CNS) effects, while chronic toxicity has mainly pulmonary effects. Severe cases of oxygen toxicity can lead to cell damage and death. Those at particular risk for oxygen toxicity include hyperbaric oxygen therapy patients, patients exposed to prolonged high levels of oxygen, premature infants, and underwater divers. 
Extended exposure to above-normal oxygen partial pressures, or shorter exposures to very high partial pressures, can cause oxidative damage to cell membranes leading to the collapse of the alveoli in the lungs. Pulmonary effects can present as early as within 24 hours of breathing pure oxygen. Symptoms include pleuritic chest pain, substernal heaviness, coughing, and dyspnea secondary to tracheobronchitis and absorptive atelectasis which can lead to pulmonary edema. Pulmonary symptoms typically abate 4 hours after cessation of exposure in the majority of patients. CNS effects manifest with a multitude of potential symptoms. Early symptoms and signs are quite variable, but twitching of perioral and small muscles of the hand is a fairly consistent feature. If exposure to oxygen pressures is sustained tinnitus, dysphoria, nausea, and generalized convulsions can develop. CNS toxicity is expedited by factors such as raised PCO2, stress, fatigue and cold .
The CNS effects secondary to oxygen toxicity is known as the Bert effect. This can occur with hyperbaric oxygen therapy in a dose-dependent corelation. The overall risk may be as frequent as 1 in 2000 to 3000 treatments. However, this risk may be as high as 1 in 200 at higher pressures (2.8 to 3.0 times normal atmospheric pressure or one atmosphere absolute (ATA)) and as low as 1 in 10,000 for treatment at 2 ATA (atmosphere absolute air) or less. The incidence of displaying CNS symptoms secondary to oxygen toxicity is 2% with a seizure rate of 0.6%.
The phenomenon of pulmonary toxicity is commonly referred to as the Smith effect. This can occur after prolonged exposure to oxygen >0.5 ATA. The incidence of displaying pulmonary symptoms with oxygen toxicity is 5%. Preterm newborns are at distinct risk for bronchopulmonary dysplasia and retrolental fibroplasia with prolonged exposure to high concentrations of oxygen.
Some chemicals such as the chemotherapeutic agent bleomycin also increase the risk of oxygen toxicity .
Oxygen-derived free radicals have been proposed as being the probable etiological cause in the development of oxygen toxicity. Free radicals are generated due to the mitochondrial oxidoreductive processes and also induced by the function of enzymes such as xanthine/urate oxidase at extra-mitochondrial sites, from auto-oxidative reactions, and by phagocytes during the bacterial killing. These free radicals create lipid peroxidations, especially in the cell membranes, subdue nucleic acids and protein synthesis, and mollify cellular enzymes. Continued exposure to high concentrations of oxygen results in heightened free radical production. This may damage the pulmonary epithelium, inactivate the surfactant, form intra-alveolar edema, interstitial thickening, fibrosis, and ultimately lead to pulmonary atelectasis.
Oxygen toxicity stimulates the development of histological changes in the lung. This consists of pulmonary edema, congestion, intra-alveolar hemorrhage, and pulmonary injury. Tissue examination reveals that surfactant interruption and epithelial injury initiate the expanded expression of cytokines that activate inflammatory cells. The heightened release of oxygen free radicals modifies normal endothelial function. Microscopic examination at high magnification display the alveoli in the lung filled with smooth to slight floccular pink material characteristic of pulmonary edema and congestion. The capillaries in the alveolar walls are congested with many red blood cells.
100% oxygen can be tolerated at sea level for about 24-48 hours without any severe tissue damage. Lengthy exposures produce definite tissue injury. There is moderate carinal irritation on deep inspiration after 3-6 hours of exposure of 2 ATA, extreme carinal irritation with uncontrolled coughing after 10 hours, and finally, chest pain and dyspnea ensue. In a majority of patients, these symptoms subside 4 hours after cessation of exposure.
Symptoms may include disorientation, breathing problems, and visual changes such as myopia and cataract formation.
Central nervous system signs and symptoms:
Pulmonary toxicity signs and symptoms:
Patients at risk for pulmonary oxygen toxicity should be monitored for oxygen saturation and elevated work of breathing. They can be evaluated by pulmonary function testing and chest x-ray which can show signs of acute respiratory distress syndrome (ARDS). Similarly, eye exams assessing acuity and looking for lens opacification can be done to detect early ocular oxygen toxicity. CNS toxicity manifests as described above and will often have associated tachycardia and diaphoresis. Aborting a hyperbaric exposure when these signs are present can prevent seizure occurrence .
Oxygen toxicity is managed by reducing the exposure to increased oxygen levels. The lowest possible concentration of oxygen that alleviates tissue hypoxia is optimal in patients with ARDS and decompensated neonates who are at particular risk for retrolental fibroplasia. Oxygen-induced seizures are self-limited and do not increase susceptibility to epilepsy. There is concern that oxygen-induced seizures could lead to damage but are felt to be benignant and similar to febrile seizures in children, where no particular treatment is available .
For hyperbaric oxygen treatments, those at high risk may benefit from anti-epileptic therapy, prolonged air breaks, and limited treatment pressure. Protocols for the avoidance of hyperoxia exist in fields where oxygen is breathed at higher-than-normal partial pressures. This comprises underwater diving using compressed breathing gases, neonatal care, hyperbaric medicine, and human spaceflight. The present protocols have diminished the incidence of seizures due to oxygen toxicity, with pulmonary and ocular damage being mainly confined to the problems of managing premature infants. Oxygen toxicity seizures during hyperbaric therapy have also been curtailed by the introduction of "air breaks" (intermittent air-breathing while in the hyperbaric environment). This intervention may lower risk by a factor of 10. 
Deep divers (diving below 185 feet) require breathing mixtures that contain less than 21% oxygen to reduce toxicity risk. At these depths, the mixture is changed from nitrogen to helium as well. Underwater seizures require immediate ascent as the risk of pulmonary barotrauma, and decompression illness is offset by the extraordinarily high risk of fatal drowning .
Several conditions can be mistaken for oxygen toxicity. Typically diagnosis is made clinically and can be confirmed with PaO2 (arterial oxygen levels). The following conditions must be ruled out when clinically evaluating for oxygen toxicity :
Treatment for oxygen toxicity is purely symptomatic, therefore it is imperative to monitor for early recognition of toxicity . It should be remembered that the sudden stoppage of oxygen at the onset of toxicity may at times aggravate symptoms. The onset and rate of progression of oxygen toxicity can be influenced by a variety of conditions, procedures and drugs. Induction of antioxidant enzymes, such as superoxide dismutase, by exposure to non-lethal levels of hyperoxia/hypoxia isoloated or conjointly has been tried successfully in animals and is in the process of being evaluated in man . It is thought that this may lead to the progression of tolerance to subsequent hyperoxic exposure. Exogenous antioxidants, notably vitamin E and C have been found to lower the prevalence of retrolental fibroplasia in premature infants on hyperoxic therapy .
For adults, although central nervous system oxygen toxicity may lead to incidental injury, studies show that with the removal of the inciting agent no long term neurological damage occurs . Damage due to oxygen-induced pulmonary toxicity is reversible in most adults.
For infants, those who have survived following an incidence of bronchopulmonary dysplasia will ultimately recover near-normal lung function, since lungs continue to grow during the first 5–7 years. Nevertheless, they are likely to be more vulnerable to respiratory infections for the rest of their lives, and the harshness of later infections is often greater than that in their peers .
Retinopathy of prematurity (ROP) in infants frequently reverses without intervention and eyesight may be normal in later years. When the disease has advanced to the stages requiring surgery, the results are generally good for the treatment of stage 3 ROP, but are much worse for the later stages. Although surgery is usually successful in restoring the anatomy of the eye, damage to the nervous system by the progression of the disease leads to comparatively poorer results in restoring vision. The presence of other complicating diseases also reduces the likelihood of a favourable outcome .
Oxygen toxicity can cause a variety of complications affecting multiple organ systems. CNS complications primarily include tonic-clonic convulsions and amnesia. Pulmonary sequelae range from mild tracheobronchitis and absorptive atelectasis to diffuse alveolar damage that is indistinguishable from ARDS. Ocular complications consist of reversible myopia, delayed cataract formation, and in children, retrolental fibroplasia. Serous otitis media and dysbaric osteonecrosis have also been observed. In patients with chronic obstructive pulmonary disease (COPD), status asthmaticus, weakness of the respiratory muscles (e.g., from polyneuritis, poliomyelitis, or myasthenia gravis) and in those with central respiratory depression from narcotic poisoning, head injury, or raised intracranial tension, oxygen toxicity can cause carbon dioxide narcosis secondary to a loss in the hypoxemic drive and decrease in ventilation .
The major limitation facing a much more abundant clinical use of hyperoxia is its probable toxicity and the relatively limited margin of safety that exists between its effective and toxic doses. However, an alertness of the toxic effects of oxygen and a familiarity with safe pressure and duration, limits its application. Moreover, the capacity to carefully manage its dose provides a sufficient basis for broadening the current list of clinical indications for its use. The most obvious toxic manifestations of oxygen are those exerted on the respiratory system and central nervous system.
There is wide variability in susceptibility to oxygen toxicity. Increased seizure risk is linked to retention of carbon dioxide, underwater immersion, exposure to cold, and exercise. Scuba divers use breathing gases containing up to 100% oxygen (e.g., enriched air nitrox, closed circuit rebreathers) and should have specific training in safe use. In recent years, oxygen has become available for recreational use in oxygen bars. The FDA warns those suffering from problems such as heart or lung disease not to use oxygen bars .
Although there is a steadily growing body of data on hyperoxia, the quantity of high-quality information on its clinical effects trails behind. The present list of evidence-based indications for hyperoxia is much more limited than the broad spectrum of clinical conditions such as impaired oxygen delivery, cellular hypoxia, tissue edema, inflammation, and infection that can potentially be mitigated by oxygen therapy.
The easy accessibility of normobaric hyperoxia calls for a much more dynamic attempt to characterize its potential clinical efficacy. The all-around beneficial profile of actions of hyperoxia justifies an appropriately funded prospective research approach that will establish the efficacy of a safe range of nontoxic doses and treatment duration.
|||Hyperoxia in intensive care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update., Hafner S,Beloncle F,Koch A,Radermacher P,Asfar P,, Annals of intensive care, 2015 Dec [PubMed PMID: 26585328]|
|||Oxygen toxicity., Thomson L,Paton J,, Paediatric respiratory reviews, 2014 Jun [PubMed PMID: 24767867]|
|||Side effects of hyperbaric oxygen therapy., Camporesi EM,, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc, 2014 May-Jun [PubMed PMID: 24984321]|
|||Oxygen toxicity seizures: 20 years' experience from a single hyperbaric unit., Banham ND,, Diving and hyperbaric medicine, 2011 Dec [PubMed PMID: 22183697]|
|||Matalon S,Nesarajah MS,Farhi LE, Pulmonary and circulatory changes in conscious sheep exposed to 100% O2 at 1 ATA. Journal of applied physiology: respiratory, environmental and exercise physiology. 1982 Jul [PubMed PMID: 6811521]|
|||Brock TG,Di Giulio C, Prolonged exposure to hyperoxia increases perivascular mast cells in rat lungs. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2006 Nov [PubMed PMID: 16899761]|
|||Wingelaar TT,van Ooij PAM,Brinkman P,van Hulst RA, Pulmonary Oxygen Toxicity in Navy Divers: A Crossover Study Using Exhaled Breath Analysis After a One-Hour Air or Oxygen Dive at Nine Meters of Sea Water. Frontiers in physiology. 2019 [PubMed PMID: 30740057]|
|||OXYGEN TOXICITY., Chawla A,Lavania AK,, Medical journal, Armed Forces India, 2001 Apr [PubMed PMID: 27407317]|
|||Hyperbaric oxygen-induced seizures cause a transient decrement in cognitive function., Domachevsky L,Rachmany L,Barak Y,Rubovitch V,Abramovich A,Pick CG,, Neuroscience, 2013 Sep 5 [PubMed PMID: 23732232]|
|||Neurological oxygen toxicity., Farmery S,Sykes O,, Emergency medicine journal : EMJ, 2012 Oct [PubMed PMID: 21900296]|
|||Ni YN,Wang YM,Liang BM,Liang ZA, The effect of hyperoxia on mortality in critically ill patients: a systematic review and meta analysis. BMC pulmonary medicine. 2019 Feb 26 [PubMed PMID: 30808337]|
|||Neal M,Richardson JR, Time to get Personal: A Framework for Personalized Targeting of Oxidative Stress in Neurotoxicity and Neurodegenerative Disease. Current opinion in toxicology. 2018 Feb [PubMed PMID: 30272040]|
|||Stone CA Jr,McEvoy CT,Aschner JL,Kirk A,Rosas-Salazar C,Cook-Mills JM,Moore PE,Walsh WF,Hartert TV, Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia. Neonatology. 2018 [PubMed PMID: 29514147]|
|||[PubMed PMID: 30597674]|
|||[PubMed PMID: 30839172]|
|||[PubMed PMID: 30772472]|
|||[PubMed PMID: 28790955]|
|||Effects of elevated oxygen and carbon dioxide partial pressures on respiratory function and cognitive performance., Gill M,Natoli MJ,Vacchiano C,MacLeod DB,Ikeda K,Qin M,Pollock NW,Moon RE,Pieper C,Vann RD,, Journal of applied physiology (Bethesda, Md. : 1985), 2014 Aug 15 [PubMed PMID: 24947022]|